

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 May 12 EXTEND option available in structure searching
NEWS 4 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5 May 27 New UPM (Update Code Maximum) field for more efficient patent
SDIs in CAPlus
NEWS 6 May 27 CAPlus super roles and document types searchable in REGISTRY
NEWS 7 Jun 22 STN Patent Forums to be held July 19-22, 2004
NEWS 8 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS 9 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
and WATER from CSA now available on STN(R)
NEWS 10 Jul 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7
DICTIONARY FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.63

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 05:51:58 ON 13 JUL 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ


PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 05:58:29 ON 13 JUL 2004
FILE 'REGISTRY' ENTERED AT 05:58:29 ON 13 JUL 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.63

=>

Uploading C:\Examination Auxillary files\09995987\09995987 electd specie.str



chain nodes :

1 2 3 4 5 6 8 9 10 11 12 18 19 20 21 40 41 42 43 44

ring nodes :

7 13 14 15 16 17 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
37 38 39

chain bonds :

1-2 1-44 2-3 2-8 3-4 3-9 3-10 4-5 5-6 5-11 6-7 6-12 15-18 18-19 19-20
19-23 20-21 20-40 21-22 21-43 26-29 36-41 38-42

ring bonds :

7-13 7-17 13-14 14-15 15-16 16-17 22-35 22-39 23-24 23-28 24-25 25-26
26-27 27-28 29-30 29-34 30-31 31-32 32-33 33-34 35-36 36-37 37-38 38-39

exact/norm bonds :

4-5 5-6 6-12 18-19 19-20 19-23 20-21 20-40 21-22 29-30 29-34 30-31
31-32 32-33 33-34

exact bonds :

1-44 2-3 3-4 3-9 3-10 5-11 6-7 15-18 21-43 26-29 36-41 38-42

normalized bonds :

1-2 2-8 7-13 7-17 13-14 14-15 15-16 16-17 22-35 22-39 23-24 23-28 24-25
25-26 26-27 27-28 35-36 36-37 37-38 38-39

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom
37:Atom 38:Atom 39:Atom 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> search l1 exact full
FULL SEARCH INITIATED 05:59:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA EXA FUL L1

=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanoic acid, 3-[[4-[[[4-(1-cyclohexen-1-yl)phenyl][[(3,5-dichlorophenyl)amino]carbonyl]amino]methyl]benzoyl]amino]-2,2-difluoro-(9CI)
MF C30 H27 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

52.67

52.88

FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3
FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> 12

L3 1 L2

=> d l3 ti fbib abs

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of ureidomethylbenzoylaminodifluoropropionates as glucagon antagonists/inverse agonists.
AN 2002:391685 CAPLUS
DN 136:385945
TI Preparation of ureidomethylbenzoylaminodifluoropropionates as glucagon antagonists/inverse agonists.
IN Jorgensen, Anker Steen; Madsen, Peter
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040446	A1	20020523	WO 2001-DK760	20011115
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				DK 2000-1733	A 20001117
	AU 2002023502	A5	20020527	AU 2002-23502	20011115
				DK 2000-1733	A 20001117
				WO 2001-DK760	W 20011115
	EP 1345891	A1	20030924	EP 2001-996529	20011115
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				DK 2000-1733	A 20001117
				WO 2001-DK760	W 20011115
	JP 2004513936	T2	20040513	JP 2002-542774	20011115
				DK 2000-1733	A 20001117
				WO 2001-DK760	W 20011115
	US 2003027849	A1	20030206	US 2001-995987	20011116
				DK 2000-1733	A 20001117
				US 2000-252322PP	20001120

OS MARPAT 136:385945

AB HO₂CCF₂CH₂NHCOZCHR₂N(E)XD [R₂ = H, alkyl; Z = (substituted) arylene, heteroarylene; X = (CH₂)_q(CR₁₂R₁₃)_r(CH₂)_s, CO(CR₁₂R₁₃)_r(CH₂)_s, NR₁₁CO(CR₁₂R₁₃)_r(CH₂)_s, etc.; r = 0, 1; s = 0-3; R₁₁, R₁₂, R₁₃ = H, alkyl; D = (substituted) Ph, naphthyl, pyridyl, indenyl, benzothienyl, thienyl, furyl, benzofuryl, etc.; E = (substituted) cyclohexyl, Ph, PhCH₂, PhCH₂CH₂, indanyl, benzhydryl, etc.], were prepared Thus, Me 4-[(4-cyclohex-1-enylphenylamino)methyl]benzoate (preparation given) in CH₂Cl₂ containing diisopropylethylamine was treated with 3,5-dichlorophenyl isocyanate to give a residue which was saponified with LiOH. The resulting acid in DMF was treated with 3-[(dimethyliminium)(dimethylamino)methyl]-1,2,3-benzotriazol-1-ium-1-olate hexafluorophosphate,

diisopropylethylamine, Me 3-amino-2,2-difluoropropionate hydrochloride to give the uncharacterized amide ester, which was saponified with aqueous LiOH in THF/MeOH to give 3-[4-[1-(4-cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]benzoylamino]-2,2-difluoropropionic acid. In a human glucagon receptor binding assay, title compds. showed IC50<1000 nM.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.94

63.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.74

-0.74

FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7

DICTIONARY FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Examination Auxillary files\09995987\09995987 first try.str



chain nodes :

1 2 3 4 5 6 8 9 10 11 12 18

ring nodes :

7 13 14 15 16 17

chain bonds :

1-2 1-18 2-3 2-8 3-4 3-9 3-10 4-5 5-6 5-11 6-7 6-12

ring bonds :

7-13 7-17 13-14 14-15 15-16 16-17

exact/norm bonds :

4-5 5-6 6-12
 exact bonds :
 1-18 2-3 3-4 3-9 3-10 5-11 6-7
 normalized bonds :
 1-2 2-8 7-13 7-17 13-14 14-15 15-16 16-17

Match level :


1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:CLASS 9:CLASS
 10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l4 sss sam

SAMPLE SEARCH INITIATED 06:10:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 159 TO 721

PROJECTED ANSWERS: 2 TO 124

L5 2 SEA SSS SAM L4

=> d scan


L5 2 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN 2H-Pyran-4-propanoic acid, β -(benzoylamino)- α,α -
 difluorotetrahydro- (9CI)
 MF C15 H17 F2 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L5 2 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Propanoic acid, 3-[[4-[[[(3,5-dichlorophenyl)amino]carbonyl][4-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]amino]methyl]benzoyl]amino]-2,2-difluoro- (9CI)
 MF C34 H35 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> search l4 sss full
 FULL SEARCH INITIATED 06:11:12 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 360 TO ITERATE


100.0% PROCESSED 360 ITERATIONS
 SEARCH TIME: 00.00.01

6 ANSWERS

L6 6 SEA SSS FUL L4

=> d scan


L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Cyclohexanepropanoic acid, β-(benzoylamino)-α,α-difluoro- (9CI)
 MF C16 H19 F2 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN 2-Furanpropanoic acid, β -(benzoylamino)- α,α -difluoro-
 (9CI)
 MF C14 H11 F2 N O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN 2H-Pyran-4-propanoic acid, β -(benzoylamino)- α,α -
 difluorotetrahydro- (9CI)
 MF C15 H17 F2 N O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Propanoic acid, 3-[[4-[[[4-(1-cyclohexen-1-yl)phenyl][[(3,5-
 dichlorophenyl)amino]carbonyl]amino]methyl]benzoyl]amino]-2,2-difluoro-
 (9CI)
 MF C30 H27 Cl2 F2 N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Propanoic acid, 3-[[4-[[[(3,5-dichlorophenyl)amino]carbonyl][4-[4-(1,1-dimethylethyl)-1-cyclohexen-1-yl]phenyl]amino]methyl]benzoyl]amino]-2,2-difluoro- (9CI)
 MF C34 H35 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 6 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Benzenepropanoic acid, β-(benzoylamino)-α,α-difluoro- (9CI)
 MF C16 H13 F2 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	155.84	219.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.74

FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3
 FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l6

L7 2 L6

=> d his

(FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004)

FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004

L1 STRUCTURE UPLOADED
 L2 1 SEARCH L1 EXACT FULL

FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004

L3 1 L2

FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004

L4 STRUCTURE UPLOADED
 L5 2 SEARCH L4 SSS SAM
 L6 6 SEARCH L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004

L7 2 L6

=> l7 not l3


L8 1 L7 NOT L3

=> d l8 ti fbib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
 TI Preparation of taxol derivatives as antitumors
 AN 1995:973637 CAPLUS
 DN 124:9049

TI Preparation of taxol derivatives as antitumors
 IN Terasawa, Hirofumi; Soga, Tsunehiko; Uoto, Koichi
 PA Daiichi Seiyaku Co, Japan
 SO Jpn. Kokai Tokkyo Koho, 37 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07233159	A2	19950905	JP 1994-314474	19941219
	JP 3400582	B2	20030428		
				JP 1994-314474 A	19941219
				JP 1993-319888	19931220
OS	MARPAT 124:9049				
GI					



AB The title compds. [I; X = halo; R1 = protected amino, Z-R6; R6 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; Z = NH, O, CO2, etc.; R2 = (un)substituted alkyl, (un)substituted alkenyl, aryl, etc.; R3 = H, alkyl, halo; R4 = H, protecting group; R5 = H, protecting group] are prepared. Thus, a mixture of 7,10-bis(2,2,2-trichloroethoxycarbonyl)-10-deacetylbaecatin III and 3-(tert-butoxycarbonylamino)-2,2-difluoro-3-phenylpropionic acid (preparation given) in toluene containing 4-(dimethylamino)pyridine and di-2-pyridyl carbonate was heated at 80° for 60 h to give I [R1 = tBu-O2C-NH, R2 = Ph, R3 = X = fluoro, R4 = R5 = CO2-CH2-CCl3], which was treated with zinc in HOAc-MeOH at 60° for 15 min to give I [R1 = tBu-O2C-NH, R2 = Ph, R3 = X = fluoro, R4 = R5 = H]. In an in vitro study using P388 tumor cells, this had a GI50 value (concentration inhibiting 50% of tumor cell growth) of 21.0 ng/mL vs. taxol's 30.4 ng/mL.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.97

224.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.74

-1.48

FILE 'REGISTRY' ENTERED AT 06:14:36 ON 13 JUL 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7
DICTIONARY FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Examination Auxillary files\09995987\09995987 second try.str



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 14

chain bonds :

1-2 1-12 2-3 2-7 3-4 3-8 3-9 4-5 5-6 5-10 6-11 6-14

exact/norm bonds :

4-5 5-6 6-11 6-14

exact bonds :

1-12 2-3 3-4 3-8 3-9 5-10

normalized bonds :

1-2 2-7

G1:C,O,S,N

Match level :


1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 14:CLASS

L9 STRUCTURE UPLOADED

=> d 19

L9 HAS NO ANSWERS

L9 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> search l9 sss sam

SAMPLE SEARCH INITIATED 06:15:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 8 TO 329

PROJECTED ANSWERS: 3 TO 163


L10 3 SEA SSS SAM L9

=> d scan

L10 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN D-Valine, N-[N-(5-amino-5-carboxy-1-oxopentyl)-3,3-difluoro-L- α -
aspartyl]-, (S)- (9CI)

MF C15 H23 F2 N3 O8




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L10 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN


IN 3-Furanpropanoic acid, β -[[[(1,1-dimethylethoxy)carbonyl]amino]-
 α,α -difluoro- (9CI)

MF C12 H15 F2 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN 2-Benzofuranpropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
 α,α-difluoro- (9CI)
 MF C16 H17 F2 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Examination Auxillary files\09995987\09995987 second try v.2

L11 STRUCTURE UPLOADED

=> d 111

L11 HAS NO ANSWERS

L11 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> search 111 sss sam

SAMPLE SEARCH INITIATED 06:18:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**
 PROJECTED ITERATIONS: 8 TO 329
 PROJECTED ANSWERS: 2 TO 124

L12 2 SEA SSS SAM L11

=> d scan


L12 2 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN 2H-Pyran-4-propanoic acid, β -(benzoylamino)- α,α -
 difluorotetrahydro- (9CI)
 MF C15 H17 F2 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 2 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Propanoic acid, 3-[[4-[[[(3,5-dichlorophenyl)amino]carbonyl][4-[4-(1,1-
 dimethylethyl)-1-cyclohexen-1-yl]phenyl]amino]methyl]benzoyl]amino]-2,2-
 difluoro- (9CI)
 MF C34 H35 Cl2 F2 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> search l11 sss full

FULL SEARCH INITIATED 06:19:02 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 90 TO ITERATE

100.0% PROCESSED 90 ITERATIONS
SEARCH TIME: 00.00.01

6 ANSWERS

L13 6 SEA SSS FUL L11

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

158.36

382.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-1.48

FILE 'CAPLUS' ENTERED AT 06:19:08 ON 13 JUL 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3

FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l13

L14 2 L13

=> dhis

L15 18 DHIS

=> d his

(FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004)

FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004

L1 STRUCTURE UPLOADED

L2 1 SEARCH L1 EXACT FULL

FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004

L3 1 L2

FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004

L4 STRUCTURE UPLOADED

L5 2 SEARCH L4 SSS SAM

L6 6 SEARCH L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004

L7 2 L6

L8 1 L7 NOT L3

FILE 'REGISTRY' ENTERED AT 06:14:36 ON 13 JUL 2004
L9 STRUCTURE UPLOADED
L10 3 SEARCH L9 SSS SAM
L11 STRUCTURE UPLOADED
L12 2 SEARCH L11 SSS SAM
L13 6 SEARCH L11 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:19:08 ON 13 JUL 2004
L14 2 L13
L15 18 DHIS

=> l154 not l7
L154 NOT FOUND
The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> l14 not l7
L16 0 L14 NOT L7

=> logoff hold		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.83	385.82
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.48

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:20:22 ON 13 JUL 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 06:25:34 ON 13 JUL 2004
FILE 'CAPLUS' ENTERED AT 06:25:34 ON 13 JUL 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.83	385.82
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.48

=> d his

(FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004)

FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004
L1 STRUCTURE UPLOADED
L2 1 SEARCH L1 EXACT FULL

FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004

L3 1 L2

FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004

L4 STRUCTURE UPLOADED
L5 2 SEARCH L4 SSS SAM
L6 6 SEARCH L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004

L7 2 L6
L8 1 L7 NOT L3

FILE 'REGISTRY' ENTERED AT 06:14:36 ON 13 JUL 2004

L9 STRUCTURE UPLOADED
L10 3 SEARCH L9 SSS SAM
L11 STRUCTURE UPLOADED
L12 2 SEARCH L11 SSS SAM
L13 6 SEARCH L11 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:19:08 ON 13 JUL 2004

L14 2 L13
L15 18 DHIS
L16 0 L14 NOT L7

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.29	386.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.48

FILE 'MARPAT' ENTERED AT 06:26:03 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 141 ISS 02) (20040709/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6740668 25 MAY 2004
DE 10351214 08 APR 2004
EP 1422285 26 MAY 2004
JP 2004149515 27 MAY 2004
WO 2004043951 27 MAY 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> l13

SAMPLE SEARCH INITIATED 06:26:10 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED - 2290 TO ITERATE

43.7% PROCESSED 1000 ITERATIONS 15 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.06

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 43271 TO 48329
PROJECTED ANSWERS: 335 TO 1039

L17 15 SEA SSS SAM L11

=> d scan

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN

IC ICM C07C229-28

NCL 560041000

CC 30-20 (Terpenes and Terpenoids)

Section cross-reference(s): 34

TI Enzymic reduction method for the preparation of compounds useful for preparing taxanes

ST benzoylphenylisoserine enzymic stereoselective prepn; taxane intermediate
benzoylphenylisoserine enzymic prepn; bezoylaminooxophenylpropionate
stereoselective redn Hansenula

IT Hansenula polymorpha

(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)

IT Reduction

(enzymic, stereoselective preparation of the taxane side chain intermediates by enzymic reduction)

IT 1605-68-1P, Taxane 33069-62-4P, Taxol

RL: PNU (Preparation, unclassified); PREP (Preparation)

(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)

IT 2835-06-5, DL-Phenylglycine

RL: RCT (Reactant); RACT (Reactant or reagent)

(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)

IT 29670-63-1P, DL-N-Benzoylphenylglycine 153433-79-5P 167095-12-7P
167095-14-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)

IT 153433-80-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(stereoselective preparation of the taxane side chain intermediates by enzymic reduction)


MSTR 2



G2 = Ak<BD (0-) D (0-) T> (SO (1-) G5)

G5 = F / CO2H

G9 = 186-1 187-185



G10 = Hy (SO (1-) G7)

DER: or salts

MPL: disclosure

STE: as single isomers or mixtures of R and S isomers

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
IC ICM A61K049-04
NCL 424009451
CC 25-18 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 8, 63
TI Polyiodinated aroyloxy esters useful as contrast agents in x-ray imaging
compositions
ST iodinated aroyloxy ester contrast agent; x ray imaging contrast agent
iodinated
IT Imaging
(x-ray, contrast agents, polyiodinated aroyloxy esters useful as
contrast agents in x-ray imaging compns.)
IT 737-31-5, Sodium diatrizoate 14660-52-7, Ethyl 5-bromovalerate
25542-62-5, Ethyl 6-bromohexanoate
RL: RCT (Reactant); RACT (Reactant or reagent)
(polyiodinated aroyloxy esters useful as contrast agents in x-ray
imaging compns.)
IT 156644-63-2P, Win 68061 156946-45-1P, Win 67722 156971-69-6P, Win
68136 156971-70-9P, Win 67954 156971-71-0P, Win 67995 156971-72-1P,
Win 68039 156971-74-3P, Win 68166 156971-75-4P, Win 68767
156971-76-5P, Win 68888 156971-77-6P, Win 68384 156971-78-7P, Win
68038 156971-79-8P, Win 69732 173993-95-8P, Win 68060 173993-96-9P,
Win 70467 173993-97-0P, Win 71300 173993-98-1P, Win 72313
173994-07-5P, Win 69943 173994-08-6P, Win 69944 173994-09-7P, Win
69979 174024-56-7P, Win 22256
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(x-ray imaging contrast agent; polyiodinated aroyloxy esters useful as
contrast agents in x-ray imaging compns.)

MSTR 2

G11-C(O)-G5-O-G1-C(O)-O-G5-C(O)-G11

G5 = alkylene<EC (5-21) C, DC (0) M3> (SO (1-) G7)
G7 = F / 41

C(O)-G8
41

G8 = Hy<EC (1-) N, AN (1) N, RC (1), RS (1) M4 (1) X7>
G9 = NH
MPL: claim 9

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
IC ICM C08K005-098
ICS C08K005-12; C08K005-15; C08L023-02
CC 37-6 (Plastics Manufacture and Processing)
Section cross-reference(s): 24
TI Manufacture of crystal nucleating agents for polyolefins, and polyolefin
compositions
ST polyolefin crystal nucleation agent manuf; bicyclooctenedicarboxylic
anhydride methanolysis sapon polyolefin nucleation;
bicyclooctenedicarboxylate ester salt manuf polyolefin nucleation
IT Crystal nucleating agents

(manufacture of crystal nucleating agents for polyolefins)

IT Polyolefins
 RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)

(manufacture of crystal nucleating agents for polyolefins)

IT 124-30-1, Octadecylamine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amidation of norbornenedicarboxylic anhydride; manufacture of crystal nucleating agents for polyolefins)

IT 1200-88-0P 23838-82-6P, Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid disodium salt 126809-55-0P 210362-60-0P 210362-61-1P 210362-62-2P 210362-63-3P 210362-64-4P
 RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)

(manufacture of crystal nucleating agents for polyolefins)

IT 465-48-5 210362-65-5 210362-66-6 210362-67-7 210362-68-8
 RL: MOA (Modifier or additive use); USES (Uses)

(manufacture of crystal nucleating agents for polyolefins)

IT 9003-07-0, Polypropylene
 RL: MSC (Miscellaneous)

(manufacture of crystal nucleating agents for polyolefins)

IT 9010-79-1, Petrothene PP 8310GO
 RL: PRP (Properties)

(manufacture of crystal nucleating agents for polyolefins)

IT 6708-37-8, Bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic anhydride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (methanolysis and partial saponification; manufacture of crystal nucleating agents for polyolefins)


IT 826-62-0, Norborn-5-ene-2,3-dicarboxylic anhydride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (methanolysis; manufacture of crystal nucleating agents for polyolefins)

IT 5826-73-3P, Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid dimethyl ester 31517-37-0P, Bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic acid dimethyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and partial saponification; manufacture of crystal nucleating agents for polyolefins)

IT 3813-52-3, Norborn-5-ene-2,3-dicarboxylic acid 34487-58-6, Bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (salification with LiOH; manufacture of crystal nucleating agents for polyolefins)

IT 142186-01-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (saponification; manufacture of crystal nucleating agents for polyolefins)

MSTR 1



G1 = Ak<EC (1-18) C, BD (0-) D (0) T>

G2 = 9

G(O)G3

G3 = 12

G4
|
N—G4
12

G4 = alkyl<(1-18)> (SO (1-) G5)

G5 = X / CO2H

G8 = 17-1 18-3

G(O)G9
17 18

G9 = O

G14 = Ak<EC (1-18) C, BD (0-) D (0) T>

DER: or salts

MPL: claim 1

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN

IC ICM C07D239-94

ICS A61K031-505; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

TI Preparation of bicyclic amine derivatives as inhibitors of class 1
receptor tyrosine kinases

ST bicyclic amine deriv prepn tyrosine kinase inhibitor;
quinazolinylbenzenesulfonamide prepn tyrosine kinase inhibitor

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of bicyclic amine derivs. as inhibitors
of class 1 receptor tyrosine kinases)

IT Antitumor agents
Fibrosis
Psoriasis

(preparation of bicyclic amine derivs. as inhibitors of class 1 receptor
tyrosine kinases)

IT Artery, disease
(restenosis; preparation of bicyclic amine derivs. as inhibitors of class 1
receptor tyrosine kinases)

IT 364038-72-2P 364038-73-3P 364038-74-4P 364038-75-5P 364038-76-6P
364038-77-7P 364038-78-8P 364038-79-9P 364038-80-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic amine derivs. as inhibitors of class 1 receptor
tyrosine kinases)

IT 141436-78-4, Protein kinase c


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(preparation of bicyclic amine derivs. as inhibitors of class 1 receptor
tyrosine kinases)

IT 70-55-3, 4-Methylbenzenesulfonamide 98-64-6, 4-Chlorobenzenesulfonamide
701-34-8, 4-Bromobenzenesulfonamide: 1129-26-6, 4-
Methoxybenzenesulfonamide 6961-82-6, 2-Chlorobenzenesulfonamide:

13790-39-1, 4-Chloro-6,7-dimethoxyquinazoline 17260-71-8,
 3-Chlorobenzenesulfonamide 53730-99-7, 2-Iodobenzenesulfonamide
 73542-86-6, 2-Cyanobenzenesulfonamide 92748-09-9, 2-
 Bromobenzenesulfonamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of bicyclic amine derivs. as inhibitors of class 1 receptor
 tyrosine kinases)

MSTR 1



G8 = Ak<EC (1-6) C, BD (0-) D (0-) T> (SO (1-3) G9)
 G9 = F / CO2H (SO) / 141

HN—C(O)—G10
 141

G10 = heteroaryl
 MPL: claim 1
 NTE: or salts, solvates, hydrates, and N-oxides

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN
 IC ICM C07D239-91
 ICS C07D495-04; C07D513-04; A61K031-519; A61P003-04
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 TI Preparation of pyrimidinones as melanin concentrating hormone receptor 1
 antagonists
 ST pyrimidinone prepn melanin concg hormone receptor 1 antagonist
 IT Antiartherosclerotics
 Antihypertensives
 (combined with pyrimidinone melanin-concentrating hormone receptor 1
 antagonists)
 IT Mental disorder
 (depression; preparation of pyrimidinones as melanin-concentrating hormone
 receptor
 1 antagonists)
 IT Hormone receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (melanin concentrating hormone receptor 1, antagonists; preparation of
 pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)
 IT Antidepressants
 Antidiabetic agents
 Antiobesity agents
 Anxiety
 Anxiolytics
 Diabetes mellitus
 Human
 Obesity
 (preparation of pyrimidinones as melanin-concentrating hormone receptor 1
 antagonists)
 IT 515141-24-9P, 3-[4-(2-Aminoethoxy)-3-methoxyphenyl]-6-(4-
 chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one trifluoroacetate

515141-28-3P, 6-(4-Chlorophenyl)-3-[4-[2-[(4-isopropylbenzyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-51-2P,
 6-(4-Chlorophenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-75-0P,
 3-[3-Methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-7-[4-(trifluoromethyl)phenyl]-4(3H)-quinazolinone 515141-99-8P,
 6-(4-Chlorophenyl)-3-[4-[(2S,4R)-4-hydroxypyrrolidin-2-yl)methoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-03-7P,
 6-(4-Chlorophenyl)-3-[4-[(2S,4S)-4-fluoropyrrolidin-2-yl)methoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-26-4P,
 N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenyl]-4-methylbenzenesulfonamide 515142-27-5P,
 N-(3-Bromopropyl)-N-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenyl]-4-methylbenzenesulfonamide 515142-32-2P,
 6-(4-Chlorophenyl)-3-[3-methoxy-4-[(2-(pyrrolidin-1-yl)ethyl)amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-56-0P,
 6-(4-Chlorophenyl)-3-[4-[2-(dimethylamino)ethyl]amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-64-0P, 6-(4-Chlorophenyl)-3-[4-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)

IT 515141-02-3P, 3-[3-Methoxy-4-[2-(1-piperidinyl)ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-07-8P, 3-[3-Methoxy-4-[2-(4-phenyl-1-piperidinyl)ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-08-9P,
 3-[3-Methoxy-4-[2-[methyl(propyl)amino]ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-09-0P, 3-[4-[2-[Ethyl(methyl)amino]ethoxy]-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-10-3P,
 3-[4-[2-(1-Azepanyl)ethoxy]-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-11-4P, 3-[4-[2-[4-(4-Chlorophenyl)-1-piperidinyl]ethoxy]-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-12-5P,
 3-[4-[2-[Cyclohexyl(methyl)amino]ethoxy]-3-methoxyphenyl]-7-phenyl-4(3H)-quinazolinone 515141-13-6P, 3-[3-Methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-14-7P,
 3-[3-Methoxy-4-[2-[methyl(2-phenylethyl)amino]ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-15-8P, 3-[4-[2-[Benzyl(methyl)amino]ethoxy]-3-methoxyphenyl]-7-(4-fluorophenyl)-4(3H)-quinazolinone 515141-17-0P,
 3-[4-[2-(Dimethylamino)ethoxy]-3-methoxyphenyl]-7-(4-fluorophenyl)-4(3H)-quinazolinone 515141-18-1P, 3-[4-[2-[Benzyl(methyl)amino]ethoxy]-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-20-5P,
 6-(4-Chlorophenyl)-3-[4-[2-(dimethylamino)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-21-6P,
 6-(4-Chlorophenyl)-3-[4-[2-[ethyl(methyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-22-7P,
 6-(4-Chlorophenyl)-3-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-29-4P,
 6-(4-Chlorophenyl)-3-[4-[2-[(4-isopropylbenzyl)(methyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-30-7P,
 3-[4-[2-[(4-Chlorobenzyl)amino]ethoxy]-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-31-8P,
 3-[4-[2-[(4-Chlorobenzyl)(methyl)amino]ethoxy]-3-methoxyphenyl]-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-32-9P,
 6-(4-Chlorophenyl)-3-[4-[2-[(4-fluorobenzyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-33-0P,
 6-(4-Chlorophenyl)-3-[4-[2-[(4-fluorobenzyl)(methyl)amino]ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-34-1P,
 4-[[2-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenoxy]ethyl]amino]methyl]benzonitrile 515141-35-2P,
 4-[[2-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-

methoxyphenoxy]ethyl] (methyl) amino]methyl]benzonitrile 515141-36-3P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[2-(N-methylanilino)ethoxy]phenyl]thieno
[3,2-d]pyrimidin-4(3H)-one 515141-38-5P, 6-(4-Chlorophenyl)-3-[4-[2-(N-
ethyl-3-methylanilino)ethoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-
one 515141-39-6P, 4-[2-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-
d]pyrimidin-3(4H)-yl]-2-methoxyphenoxy]ethyl] (methyl) amino]benzonitrile
515141-41-0P, 3-[4-[2-[4-Chloro-N-methylanilino]ethoxy]-3-methoxyphenyl]-6-
(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-43-2P,
3-[4-[((2S)-2-Aminopropyl)oxy]-3-methoxyphenyl]-6-(4-
chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-45-4P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[(1-methyl-4-
piperidinyl)oxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-47-6P,
3-[3-Methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-6-phenylthieno[3,2-
d]pyrimidin-4(3H)-one 515141-50-1P, 6-(4-Fluorophenyl)-3-[3-methoxy-4-(2-
(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one
515141-53-4P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-
yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one maleate 515141-54-5P,
6-(4-Methoxyphenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-
yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-55-6P,
2-(4-Chlorophenyl)-6-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-
[1,3]thiazolo[4,5-d]pyrimidin-7(6H)-one 515141-57-8P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-(2-methyl-2-(pyrrolidin-1-
yl)propoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-64-7P,
6-(4-Chlorophenyl)-3-[4-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-70-5P,
6-(4-Chlorophenyl)-3-[4-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-83-0P,
7-(4-Fluoro-3-methylphenyl)-3-[3-methoxy-4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-85-2P,
3-[3-Methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-7-(4-methylphenyl)-4(3H)-
quinazolinone 515141-87-4P, 7-(4-Methoxyphenyl)-3-[3-methoxy-4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-89-6P,
7-(4-Chlorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-
quinazolinone 515141-91-0P, 7-(3-Chlorophenyl)-3-[3-methoxy-4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone maleate 515141-92-1P,
7-(4-Ethylphenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-
quinazolinone 515141-93-2P, 7-(4-Fluorophenyl)-3-[3-methoxy-4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515141-95-4P,
7-(3-Chloro-4-fluorophenyl)-3-[3-methoxy-4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone maleate 515141-96-5P,
7-(3-Fluorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-
quinazolinone 515141-97-6P, 3-[3-Chloro-4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]-7-phenyl-4(3H)-quinazolinone 515141-98-7P,
3-[3-Chloro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-7-(4-fluorophenyl)-4(3H)-
quinazolinone 515142-02-6P, 6-(4-Chlorophenyl)-3-[4-[((2S,4R)-4-hydroxy-
1-methylpyrrolidin-2-yl)methoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-
4(3H)-one 515142-05-9P, 6-(4-Chlorophenyl)-3-[4-[((2S,4S)-4-fluoro-1-
methylpyrrolidin-2-yl)methoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-
4(3H)-one maleate 515142-06-0P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[(1-
methyl-3-pyrrolidinyl)oxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one
515142-07-1P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[(1-methyl-3-
piperidinyl)methoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one
515142-08-2P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[2-[[5-(4-methylphenyl)-
1,3,4-oxadiazol-2-yl]amino]ethoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one
515142-10-6P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-(3-(pyrrolidin-1-
yl)propoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-13-9P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-(3-(piperidin-1-
yl)propoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-14-0P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-(3-morpholin-4-
ylpropoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-15-1P,
6-(4-Chlorophenyl)-3-[4-[3-(cyclopropylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-16-2P,
6-(4-Chlorophenyl)-3-[4-[3-(cyclobutylamino)propoxy]-3-

methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-17-3P,
6-(4-Chlorophenyl)-3-[4-[3-(cyclopentylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-18-4P,
6-(4-Chlorophenyl)-3-[4-[3-(cyclohexylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-19-5P,
6-(4-Chlorophenyl)-3-[4-[3-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy]-
3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-20-8P,
6-(4-Chlorophenyl)-3-[4-[3-(dimethylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-21-9P,
6-(4-Chlorophenyl)-3-[4-[3-(diethylamino)propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-22-0P,
3-[4-[3-[Benzyl(methyl)amino]propoxy]-3-methoxyphenyl]-6-(4-
chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515142-23-1P,
6-(4-Chlorophenyl)-3-[4-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-24-2P,
N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
methoxyphenyl]-2-(pyrrolidin-1-yl)acetamide 515142-28-6P,
N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
methoxyphenyl]-N-[3-(dimethylamino)propyl]-4-methylbenzenesulfonamide
515142-29-7P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl]-2-methoxyphenyl]-N-[3-(diethylamino)propyl]-4-methylbenzenesulfonamide
515142-30-0P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl]-2-methoxyphenyl]-4-methyl-N-(3-(piperidin-1-
yl)propyl)benzenesulfonamide 515142-31-1P, N-[4-[6-(4-Chlorophenyl)-4-
oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-methoxyphenyl]-4-methyl-N-(3-
(pyrrolidin-1-yl)propyl)benzenesulfonamide 515142-34-4P,
N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
methoxyphenyl]-2,2,2-trifluoro-N-(2-(pyrrolidin-1-yl)ethyl)acetamide
515142-35-5P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl]-2-methoxyphenyl]-N-(2-(pyrrolidin-1-yl)ethyl)-2-furamide
515142-36-6P, N-[4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl]-2-methoxyphenyl]-N-(2-(pyrrolidin-1-yl)ethyl)acetamide 515142-37-7P,
4-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
methoxyphenyl(2-(pyrrolidin-1-yl)ethyl)formamide 515142-38-8P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[methyl(2-(pyrrolidin-1-
yl)ethyl)amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-39-9P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[(2S)-1-methylpyrrolidin-2-
yl)methoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-41-3P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[2-(1-methylpyrrolidin-2-
yl)ethoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-43-5P,
6-(4-Chlorophenyl)-3-[4-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethoxy]-3-
methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-47-9P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-2-
methylthieno[3,2-d]pyrimidin-4(3H)-one acetate 515142-48-0P,
3-[4-[2-(Diethylamino)ethyl]amino]-3-methoxyphenyl]-6-(4-
fluorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515142-49-1P,
6-(4-Fluorophenyl)-3-[3-methoxy-4-(4-methylpiperazin-1-
yl)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-50-4P,
6-(4-Fluorophenyl)-3-[3-methoxy-4-[[3-(2-oxopyrrolidin-1-
yl)propyl]amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-51-5P,
6-(4-Fluorophenyl)-3-[3-methoxy-4-[(2-(piperidin-1-
yl)ethyl)amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-52-6P,
3-[3-Methoxy-4-[(2R)-1-methylpyrrolidin-2-yl)methoxy]phenyl]-6-
phenylthieno[3,2-d]pyrimidin-4(3H)-one 515142-53-7P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[(2R)-pyrrolidin-2-
ylmethyl]amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-54-8P,
6-(4-Chlorophenyl)-3-[3-methoxy-4-[(2S)-pyrrolidin-2-
ylmethyl]amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-55-9P,
6-(4-Fluorophenyl)-3-[3-methoxy-4-[(2R)-1-methylpyrrolidin-2-
yl)methoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-57-1P,
6-(4-Chlorophenyl)-3-[4-[[2-(dimethylamino)ethyl](methyl)amino]phenyl]thie
no[3,2-d]pyrimidin-4(3H)-one hydrochloride 515142-58-2P,
6-(4-Chlorophenyl)-3-[4-[[2-(1-pyrrolidinyl)ethyl]amino]phenyl]thieno[3,2-

d]pyrimidin-4(3H)-one 515142-59-3P, 6-(4-Chlorophenyl)-3-[4-[[2-(4-morpholinyl)ethyl]amino]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-60-6P, 6-(4-Chlorophenyl)-3-[4-(4-methyl-1-piperazinyl)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-61-7P, 6-(4-Chlorophenyl)-3-[4-[[2-(diethylamino)ethyl]sulfanyl]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-63-9P, 6-(4-Chlorophenyl)-3-[4-[[2-(4-morpholinyl)ethyl]sulfanyl]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-67-3P, 6-(4-Chlorophenyl)-3-[3-methoxy-4-[2-(3-oxopyrrolidin-1-yl)ethoxy]phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-69-5P, 6-(4-Chlorophenyl)-3-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one trifluoroacetate 515142-70-8P, 6-(4-Chlorophenyl)-3-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-71-9P, 6-(4-Fluorophenyl)-3-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one hydrochloride 515142-72-0P, 5-[6-(4-Chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-(2-(pyrrolidin-1-yl)ethoxy)benzonitrile hydrochloride 515142-73-1P, 5-[6-(4-Fluorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-(2-(pyrrolidin-1-yl)ethoxy)benzonitrile hydrochloride 515142-74-2P, 6-(4-Chlorophenyl)-3-[3-fluoro-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)

IT 98-80-6, Phenylboronic acid 103-67-3, N-Methyl-N-benzylamine 109-64-8, 1,3-Dibromopropane 110-89-4, Piperidine, reactions 122-03-2, 4-Isopropylbenzaldehyde 123-75-1, Pyrrolidine, reactions 350-46-9, 4-Nitrofluorobenzene 600-00-0, Ethyl 2-bromo-2-methylpropanoate 621-63-6, 2,2-Diethoxyethanol 869-24-9, 2-(Diethylamino)ethyl chloride hydrochloride 1009-36-5, 2-Chloro-5-nitroanisole 1193-02-8, 4-Aminothiophenol 2365-48-2, Methyl thioglycolate 2799-21-5, (3R)-Pyrrolidin-3-ol 2955-88-6, 1-(2-Hydroxyethyl)pyrrolidine 3251-56-7, 4-Nitroguaiacol 3619-22-5, 4-Methylbenzohydrazide 4637-24-5, Dimethylformamide dimethyl acetal 5307-02-8, 2-Methoxybenzene-1,4-diamine 5990-17-0, Methyl 4-chlorobenzenecarbodithioate 6280-88-2, 2-Nitro-4-chlorobenzoic acid 7154-73-6, 2-(Pyrrolidin-1-yl)ethanamine 22564-43-8, N-(2-Chloroethyl)-N-ethyl-3-methylaniline 26690-80-2, tert-Butyl 2-hydroxyethylcarbamate 34381-71-0, ((2S)-1-Methylpyrrolidin-2-yl)methanol 40499-83-0, 3-Pyrrolidinol 41995-04-4, 4-Chloro-2-nitrobenzoyl chloride 50609-01-3, 4-(2-(Pyrrolidin-1-yl)ethoxy)aniline 52694-50-5, 3-(Chloromethyl)-1-methylpiperidine 84765-24-2, (2S)-2-[(tert-Butoxycarbonyl)amino]propyl p-toluenesulfonate 84877-52-1, 2-(N-Methylanilino)ethyl p-toluenesulfonate 89283-22-7, 5-Bromo-3-nitrothiophene-2-carboxaldehyde 91076-93-6, Methyl 3-amino-5-(4-chlorophenyl)thiophene-2-carboxylate 116574-74-4, 3-Fluoropyrrolidine 128796-39-4, 4-Trifluoromethylphenylboronic acid 164029-28-1, 4-(4-Nitro-2-methoxyphenoxy)-1-methylpiperidine 203866-16-4, 1-tert-Butyl 2-methyl (2S,4S)-4-fluoro-1,2-pyrrolidinedicarboxylate 316131-01-8, 3,3-Difluoropyrrolidine 394248-90-9, 3-Methoxy-4-[2-(1-pyrrolidinyl)ethoxy]aniline 515141-40-9, 2-[4-Cyano-N-methylanilino]ethyl p-toluenesulfonate 515141-42-1, 2-[4-Chloro-N-methylanilino]ethyl p-toluenesulfonate 515142-00-4, tert-Butyl (2S,4R)-2-[(4-amino-2-methoxyphenoxy)methyl]-4-hydroxypyrrolidine-1-carboxylate

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinones as melanin-concentrating hormone receptor 1 antagonists)

IT 2506-46-9P, 1-(2-Bromoethoxy)-2-methoxy-4-nitrobenzene 32515-32-5P, Ethyl 2-methyl-2-(pyrrolidin-1-yl)propanoate 40179-35-9P,


4-[[2-(Diethylamino)ethyl]sulfanyl]aniline 101079-64-5P,
 5-Bromo-3-nitrothiophene-2-carboxylic acid 101258-96-2P,
 2-Methyl-2-(pyrrolidin-1-yl)propan-1-ol 265654-77-1P,
 1-[2-(4-Nitrophenoxy)ethyl]pyrrolidine 317356-27-7P, tert-Butyl
 (2S,4S)-4-fluoro-2-(hydroxymethyl)-1-pyrrolidinecarboxylate
 476415-09-5P, tert-Butyl (2S,4S)-4-fluoro-2-[[[4-
 methylphenyl)sulfonyl]oxy]methyl]-1-pyrrolidinecarboxylate 515141-03-4P,
 4-(2,2-Diethoxyethoxy)-3-methoxyaniline 515141-04-5P,
 4-Chloro-N-[4-(2,2-diethoxyethoxy)-3-methoxyphenyl]-2-nitrobenzamide
 515141-05-6P, 7-Chloro-3-[4-(2,2-diethoxyethoxy)-3-methoxyphenyl]-4(3H)-
 quinazolinone 515141-06-7P, 3-[4-(2,2-Diethoxyethoxy)-3-methoxyphenyl]-7-
 phenyl-4(3H)-quinazolinone 515141-16-9P, 3-[4-(2,2-Diethoxyethoxy)-3-
 methoxyphenyl]-7-(4-fluorophenyl)-4(3H)-quinazolinone 515141-19-2P,
 6-(4-Chlorophenyl)-3-[4-(2,2-diethoxyethoxy)-3-methoxyphenyl]thieno[3,2-
 d]pyrimidin-4(3H)-one 515141-25-0P, tert-Butyl 2-(2-methoxy-4-
 nitrophenoxy)ethylcarbamate 515141-26-1P, tert-Butyl
 2-(4-amino-2-methoxyphenoxy)ethylcarbamate 515141-27-2P, tert-Butyl
 2-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]-2-
 methoxyphenoxy]ethylcarbamate 515141-37-4P, 6-(4-Chlorophenyl)-3-(4-
 hydroxy-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515141-44-3P,
 tert-Butyl (1S)-2-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3(4H)-
 yl]-2-methoxyphenoxy]-1-methylethylcarbamate 515141-46-5P,
 3-Methoxy-4-[(1-methyl-4-piperidinyl)oxy]aniline 515141-48-7P,
 5-Bromo-N-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-3-nitrothiophene-
 2-carboxamide 515141-49-8P, 6-Bromo-3-[3-methoxy-4-(2-(pyrrolidin-1-
 yl)ethoxy)phenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515141-52-3P, Methyl
 5-(4-chlorophenyl)-3-[[E]-(dimethylamino)methylidene]amino]-2-
 thiophenecarboxylate 515141-56-7P, Methyl 4-amino-2-(4-chlorophenyl)-1,3-
 thiazole-5-carboxylate 515141-59-0P, 1-[2-(2-Methoxy-4-nitrophenoxy)-1,1-
 dimethylethyl]pyrrolidine 515141-62-5P, 3-Methoxy-4-(2-methyl-2-
 (pyrrolidin-1-yl)propoxy)aniline 515141-66-9P, 3,3-Difluoro-1-[2-(2-
 methoxy-4-nitrophenoxy)ethyl]pyrrolidine 515141-68-1P,
 4-[2-(3,3-Difluoropyrrolidin-1-yl)ethoxy]-3-methoxyaniline 515141-72-7P,
 3-Fluoro-1-[2-(2-methoxy-4-nitrophenoxy)ethyl]pyrrolidine 515141-77-2P,
 4-Chloro-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-nitrobenzamide
 515141-79-4P, 2-Amino-4-chloro-N-[3-methoxy-4-[2-(1-
 pyrrolidinyl)ethoxy]phenyl]benzamide 515141-81-8P, 7-Chloro-3-[3-methoxy-
 4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4(3H)-quinazolinone 515142-01-5P,
 tert-Butyl (2S,4R)-2-[[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-
 3(4H)-yl]-2-methoxyphenoxy]methyl]-4-hydroxypyrrolidine-1-carboxylate
 515142-09-3P, 6-(4-Chlorophenyl)-3-[4-(2-isothiocyanatoethoxy)-3-
 methoxyphenyl]thieno[3,2-d]pyrimidin-4(3H)-one 515142-11-7P, Methyl
 5-(4-chlorophenyl)-3-[[1Z]-(dimethylamino)methylidene]amino]thiophene-2-
 carboxylate 515142-12-8P, 3-[4-(3-Bromopropoxy)-3-methoxyphenyl]-6-(4-
 chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 515142-25-3P,
 3-(4-Amino-3-methoxyphenyl)-6-(4-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-
 one 515142-33-3P, 2-Methoxy-4-nitro-N-(2-(pyrrolidin-1-yl)ethyl)aniline
 515142-40-2P, (2S)-2-[(2-Methoxy-4-nitrophenoxy)methyl]-1-
 methylpyrrolidine 515142-42-4P, 2-[2-(2-Methoxy-4-nitrophenoxy)ethyl]-1-
 methylpyrrolidine 515142-44-6P, (3R)-1-[2-(2-Methoxy-4-
 nitrophenoxy)ethyl]pyrrolidin-3-ol 515142-45-7P, 3-Amino-5-(4-
 chlorophenyl)-N-[3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thiophene-2-
 carboxamide 515142-62-8P, Methyl 5-(4-chlorophenyl)-3-
 [[(dimethylamino)methylidene]amino]-2-thiophenecarboxylate 515142-65-1P,
 1-[2-(2-Methoxy-4-nitrophenoxy)ethyl]pyrrolidin-3-ol 515142-66-2P,
 1-[2-(4-Amino-2-methoxyphenoxy)ethyl]pyrrolidin-3-ol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of pyrimidinones as melanin-concentrating hormone receptor 1
 antagonists)

H-----G18

G18 = 77



G20 = Ph / OH / F

G21 = Ak<EC (1-6) C, BD (ALL) SE> (SO (1-) G20)

MPL: claim 34

NTE: substitution is restricted

L17 15 ANSWERS MARPAT COPYRIGHT 2004 ACS on STN

IC ICM C07D495-04

ICS A61K031-519; A61P009-10

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

TI Preparation of pyrimidone and pyridone compounds as Lp-PLA2 inhibitors for treating atherosclerosis

ST pyrimidone pyridone heterocyclyl fused prepn lipoprotein phospholipase A2 inhibitor; atherosclerosis pyrimidone pyridone heterocyclyl fused thienopyrimidinone prepn

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)

IT Atherosclerosis

Human

(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)

IT Lipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)

IT 9001-84-7, Phospholipase A2 76901-00-3

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)

IT 528840-56-4P 528840-57-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)

IT 105-36-2, Ethyl bromoacetate 2689-68-1, Methyl 4-oxotetrahydrothienyl-3-carboxylate 304694-40-4, N-(2-Diethylaminoethyl)-4-(4-trifluoromethylphenyl)benzylamine 412961-31-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for treating atherosclerosis)


IT 528840-58-6P, 2-[2-(2,3-Difluorophenyl)ethyl]-5,7-dihydro-1H-thieno[3,4-d]pyrimidin-4-one 528840-59-7P, Ethyl [2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-5,7-dihydro-4H-thieno[3,4-d]pyrimidin-1-yl]acetate 528840-60-0P, [2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-5,7-dihydro-4H-thieno[3,4-d]pyrimidin-1-yl]acetic acid

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidone and pyridone compds. as Lp-PLA2 inhibitors for

treating atherosclerosis)

MSTR 1



G5 = alkylamino<(1-12)> / Hy<EC (5-7) A (1-) N (0-)
O (0-) S (0) OTHERQ, AN (1-) N> (SO)
G19 = F / 68

₆₈C(O)-G5

G32 = alkyl<(1-6)> (SO (1-3) G19)
MPL: claim 1
NTE: and pharmaceutically acceptable salts

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.26	387.54

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.48

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 06:27:54 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3
FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 05:51:43 ON 13 JUL 2004)

FILE 'REGISTRY' ENTERED AT 05:51:53 ON 13 JUL 2004

L1 STRUCTURE UPLOADED
L2 1 SEARCH L1 EXACT FULL

FILE 'CAPLUS' ENTERED AT 05:59:16 ON 13 JUL 2004

L3 1 L2

FILE 'REGISTRY' ENTERED AT 06:10:13 ON 13 JUL 2004

L4 STRUCTURE UPLOADED
L5 2 SEARCH L4 SSS SAM
L6 6 SEARCH L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:11:39 ON 13 JUL 2004

L7 2 L6
L8 1 L7 NOT L3

FILE 'REGISTRY' ENTERED AT 06:14:36 ON 13 JUL 2004

L9 STRUCTURE UPLOADED
L10 3 SEARCH L9 SSS SAM
L11 STRUCTURE UPLOADED
L12 2 SEARCH L11 SSS SAM
L13 6 SEARCH L11 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:19:08 ON 13 JUL 2004

L14 2 L13
L15 18 DHIS
L16 0 L14 NOT L7

FILE 'MARPAT' ENTERED AT 06:26:03 ON 13 JUL 2004

L17 15 L13

FILE 'CAPLUS' ENTERED AT 06:27:54 ON 13 JUL 2004

=> 117

L18 15 L17

=> d 118 1-15 ti

L18 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Process for the preparation of thieno[3,2-b]pyrrole derivatives

L18 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of pyrimidone and pyridone compounds as Lp-PLA2 inhibitors for treating atherosclerosis

L18 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Synthesis of diazabicycloalkanecarboxamides as caspase inhibitors

L18 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of pyrimidinones as melanin concentrating hormone receptor 1 antagonists

L18 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Androgen receptor modulators and methods of use thereof

L18 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of bicyclic amine derivatives as inhibitors of class 1

receptor tyrosine kinases

- L18 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Benzopyrrolone derivatives and related compds. as inhibitors of c-jun
n-terminal kinases (JNK)
- L18 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Manufacture of crystal nucleating agents for polyolefins, and polyolefin
compositions
- L18 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of amino acid heterobicyclic amide derivatives as farnesyl
transferase inhibitors
- L18 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Polyiodinated aroyloxy esters useful as contrast agents in x-ray imaging
compositions
- L18 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of phenylimidazolidines as antiandrogenics
- L18 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Enzymic reduction method for the preparation of compounds useful for
preparing taxanes
- L18 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Light-sensitive color photographic elements and process for developing
them.
- L18 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Heterocyclic HIV retroviral protease inhibitors
- L18 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of 4-nitrophenyl-1,4-dihydropyridamides as cardiovascular
agents

=> logoff hols
'HOLS' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> logoff hold
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
10.39	397.93

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.48

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:35:04 ON 13 JUL 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD: